Korsana Biosciences, Inc. — Form 8-K
Filed September 11, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 92/100
What the filing says
Cyclerion Therapeutics completed its acquisition of Korsana Biosciences on September 8, 2026. Korsana shareholders received Cyclerion common stock and Series B Non-Voting Convertible Preferred Stock (4,222 shares, 1,000:1 conversion ratio to common). Contingent value rights were issued to Korsana shareholders entitling them to 100% of net proceeds from sales of legacy assets (including Tisento equity and Akebia license agreement) during a defined period. The merger also included pre-funded warrants exercisable at $0.0001 per share.
Why this rating
For $5.7M-market-cap Korsana, becoming subsidiary of larger Cyclerion is transformational—changes ownership structure, control, and shareholder composition entirely. CVR structure with leverage to undisclosed deal economics creates material upside uncertainty.
Price action (we called it positive)
at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from September 11, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.